InvestorsObserver
×
News Home

Should You Buy Rallybio Corp (RLYB) in Biotechnology Industry?

Friday, August 12, 2022 03:59 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Rallybio Corp (RLYB) in Biotechnology Industry?

A rating of 72 puts Rallybio Corp (RLYB) near the top of the Biotechnology industry according to InvestorsObserver. Rallybio Corp's score of 72 means it scores higher than 72% of stocks in the industry. Rallybio Corp also received an overall rating of 64, putting it above 64% of all stocks. Biotechnology is ranked 28 out of the 148 industries.

Overall Score - 64
RLYB has an Overall Score of 64. Find out what this means to you and get the rest of the rankings on RLYB!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Rallybio Corp Stock Today?

Rallybio Corp (RLYB) stock is trading at $11.78 as of 3:59 PM on Friday, Aug 12, a gain of $1.11, or 10.4% from the previous closing price of $10.67. The stock has traded between $10.67 and $11.88 so far today. Volume today is light. So far 27,376 shares have traded compared to average volume of 37,631 shares. Click Here to get the full Stock Report for Rallybio Corp stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App